SynBiotic Past Earnings Performance

Past criteria checks 0/6

SynBiotic's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 30.6% per year.

Key information

-48.7%

Earnings growth rate

-37.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate30.6%
Return on equity-76.6%
Net Margin-275.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How SynBiotic makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DUSE:SBX Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 234-1130
31 Dec 228-2460
31 Dec 219-1320
31 Dec 205-110
31 Dec 190000

Quality Earnings: SBX is currently unprofitable.

Growing Profit Margin: SBX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SBX is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.

Accelerating Growth: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: SBX has a negative Return on Equity (-76.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies